Integra LifeSciences Reports First Quarter 2025 Financial Results
- 9.4% reported growth in Codman Specialty Surgical segment
- 15.1% organic growth in Instruments division
- Low double-digit growth in DuraSorb®, MicroMatrix® and Cytal® products
- Strong liquidity position of $1.16B including cash and credit facility
- GAAP net loss widened to $(25.3M) from $(3.3M) year-over-year
- Adjusted EPS declined to $0.41 from $0.55 in prior year
- Organic revenue declined 3.5% compared to prior year
- Reduced full-year adjusted EPS guidance due to tariff impact
- High leverage ratio at 4.3x
- Negative cash flow from operations of $(11.3M) in Q1
Insights
Integra's Q1 shows deteriorating financials with margin compression, negative cash flow, and reduced EPS guidance due to operational challenges.
Integra's Q1 financial performance reveals concerning trends across key metrics. Revenue reached
Margin compression is evident throughout the income statement. GAAP gross margin contracted 530 basis points to
The balance sheet shows substantial leverage with
Looking forward, management maintained full-year revenue guidance but reduced adjusted EPS guidance to
Operational challenges across both segments suggest ongoing quality and supply issues requiring significant remediation efforts.
Integra's performance reveals substantial operational hurdles affecting both business segments. In Codman Specialty Surgical (
Tissue Technologies (
Management's repeated emphasis on strengthening quality systems and improving supply reliability, coupled with the implementation of a "Compliance Master Plan," suggests systemic issues requiring substantial remediation. The appointment of new leadership in global operations and establishment of a Transformation and Program Management Office further indicates the depth of operational restructuring underway.
CEO Mojdeh Poul's candid acknowledgment of "significant work ahead" signals these challenges won't be resolved quickly. Medical device quality remediation typically requires comprehensive process overhauls that can take multiple quarters to fully implement, with revenue recovery lagging even further as customer confidence rebuilds.
PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025.
First Quarter 2025 Highlights
- First quarter revenues of
$382.7 million increased3.7% on a reported basis and decreased3.5% on an organic basis compared to the prior year. - First quarter GAAP earnings per diluted share of
$(0.33) , compared to$(0.04) in the prior year; adjusted earnings per diluted share of$0.41 , compared to$0.55 in the prior year. - Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact related to the new tariffs.
“We remain laser focused on strengthening our quality systems, improving supply reliability, and driving operational excellence. There remains significant work ahead, but we are continuing to put the processes and people in place to execute on our comprehensive Compliance Master Plan and build a foundation for sustainable performance. With the launch of our Transformation and Program Management Office and the addition of key leadership, including in global operations, we are driving improved accountability and execution across the enterprise to deliver meaningful long-term value for patients, customers, and shareholders,” said Mojdeh Poul, president and chief executive officer.
“As I reflect on my first quarter at Integra and continue spending time across our operations and with employees, I remain inspired by the deep commitment of our teams to our customers and patients. I am also encouraged by the positive feedback I consistently receive from customers about the impact of our solutions and the value of our portfolio. I’m equally optimistic about the long-term growth and earnings potential of our differentiated offerings.”
First Quarter 2025 Consolidated Performance
Total reported revenues of
The Company reported GAAP gross margin of
Adjusted EBITDA for the first quarter of 2025 was
The Company reported a GAAP net loss of
Adjusted net income for the first quarter of 2025 was
First Quarter 2025 Segment Performance
Codman Specialty Surgical (~
Total revenues were
- Sales in Neurosurgery declined
4.7% on an organic basis driven by shipping holds across several product lines - Sales in Instruments grew
15.1% on an organic basis due to strong demand and favorable prior year comparator - ENT reported revenue growth driven by the Acclarent acquisition
Tissue Technologies (~
Total revenues were
- Low double-digit growth in DuraSorb®, MicroMatrix® and Cytal®
- Low double-digit decline in Integra Skin due to production timing
- Sales in private label were down
13.3% due to a component supply delay
Advancing our Priorities
- Advancing the Compliance Master Plan and investments in supply reliability
- Expansion of international portfolio
- Integra Skin production pacing to normal revenue levels for the second quarter
- Appointed Valerie Young as CVP, global operations and supply chain
- Appointed Rick Maveus as SVP of the newly established Transformation and Program Management Office
Balance Sheet, Cash Flow and Capital Allocation
The Company generated cash flow from operations of (
As of the end of the quarter, the Company had total liquidity of approximately
2025 Outlook
For the second quarter 2025, the Company expects reported revenues in the range of
For the full year 2025, the Company is reaffirming its revenue guidance ranges of
The Company’s organic sales growth guidance for the second quarter and the full year excludes acquisitions and divestitures, as well as the effects of foreign currency. The Acclarent acquisition will be included in organic growth beginning in the second quarter of 2025.
Conference Call and Presentation Available Online
Integra has scheduled a conference call for 8:30 a.m. ET on Monday, May 5, 2025, to discuss first quarter 2025 financial results and forward-looking financial guidance. The conference call will be hosted by Integra's senior management team and will be open to all listeners. Additional forward-looking information may be discussed in a question-and-answer session following the call. Integra's management team will reference a presentation during the conference call, which can be found on the Investor section of the website at investor.integralife.com.
A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, it is recommended to join 10 minutes prior to the event’s start. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.
About Integra
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands. For the latest news and information about Integra and its products, please visit www.integralife.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” "forecast," "guidance," “plan,” “anticipate,” "target," or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this news release include, but are not limited to, statements concerning: future financial performance, including projections for revenues, expected revenue growth (both reported and organic), GAAP and adjusted net income, GAAP and adjusted earnings per diluted share, non-GAAP adjustments such as divestiture, acquisition and integration-related charges, intangible asset amortization, structural optimization charges, EU Medical Device Regulation-related charges, charges related to the voluntary global recall of all products manufactured at the Company’s facility in Boston, Massachusetts and the transition of Boston-related manufacturing operations to the Company’s Braintree, Massachusetts facility, and income tax expense (benefit) related to non-GAAP adjustments and other items; estimates regarding the projected impact of tariffs or other changes in trade policy on the Company's business, financial condition and results of operations; and the Company’s expectations and plans with respect to business and operational performance, strategic initiatives, capabilities, resources, product development, product availability and regulatory approvals, including expectations regarding the efficacy of the Company’s compliance master plan to improve the Company's quality systems. It is important to note that the Company’s goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited, to the following: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, inflation, supply chain disruptions, trade regulation and tariffs, duties or other measures implemented by the U.S. or other countries, geopolitical conflicts, and U.S. and global recession concerns, on the Company’s customers and on the Company’s business, financial condition, results of operations and cash flows; the Company's ability to execute its operating plan effectively; the Company’s ability to successfully integrate Acclarent and other acquired businesses; the Company’s ability to achieve sales growth in a timely fashion; the Company's ability to manufacture and ship sufficient quantities of its products to meet its customers' demands; the ability of third-party suppliers to supply us with raw materials and finished products; ; the Company's ability to manage its direct sales channels effectively; the sales performance of third-party distributors on whom the Company relies to generate revenue for certain products and geographic regions; the Company's ability to access and maintain relationships with customers of acquired entities and businesses; physicians' willingness to adopt and third-party payors' willingness to provide or maintain reimbursement for the Company's recently launched, planned and existing products; initiatives launched by the Company's competitors; downward pricing pressures from customers; the Company's ability to secure regulatory approval for products in development; the Company's ability to remediate quality systems violations; difficulties in implementing the Company’s compliance master plan and realizing the benefits contemplated thereby within the anticipated timeframe, or at all; difficulties or delays in obtaining and maintaining required regulatory approvals related to the transition of the manufacturing to the Company’s Braintree manufacturing facility; the possibility that costs or difficulties related to building and the operationalization of the Braintree facility or the transition of manufacturing activities from the Company’s Boston facility to the Braintree facility will be greater than expected; disruptions at the U.S. Food and Drug Administration (the “FDA”), including due to a reduction in the FDA’s workforce and/or inadequate funding for the FDA; fluctuations in hospitals' spending for capital equipment; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the Company's ability to comply with regulations regarding products of human origin and products containing materials derived from animal source; difficulties in controlling expenses, including costs to procure and manufacture the Company’s products; the ability of the Company to successfully manage leadership and organizational changes and the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the Company's ability to leverage its existing selling organizations and administrative infrastructure; the Company's ability to increase product sales and gross margins, and control non-product costs; the Company’s ability to achieve anticipated growth rates, margins and scale and execute its strategy generally; the amount and timing of divestiture, acquisition and integration-related costs; the geographic distribution of where the Company generates its taxable income; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the EU Medical Device Regulation; the scope, duration and effect of U.S. and international governmental, regulatory, fiscal, monetary and public health responses to any future public health crises; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; our ability to comply with the covenants under the agreements governing our indebtedness and the potential negative consequences caused by any non-compliance; potential negative impacts resulting from environmental, social and governance matters; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading “Risk Factors” included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2024 and information contained in subsequent filings with the Securities and Exchange Commission.
These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise, except as otherwise required by law.
Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted net income, adjusted gross margin, adjusted earnings per diluted share, and net debt. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); and (v) those operating expenses also excluded from adjusted net income. The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) charges related to the manufacturing stoppage and voluntary global recall of all products manufactured at the Company’s Boston, Massachusetts facility and distributed between March 1, 2018 and May 22, 2023, as previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 23, 2023 (the “recall”) and the transition of Boston-related manufacturing operations to the Company’s Braintree, Massachusetts facility; (v) intangible asset amortization expense; and (vi) income tax impact from adjustments. The measure of adjusted gross margin is calculated by dividing adjusted gross profit by total revenues. Adjusted gross profit consists of GAAP gross profit adjusted for: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) charges related to the recall and the transition of Boston-related manufacturing operations to the Company’s Braintree, Massachusetts facility; (iv) EU Medical Device Regulation-related charges; and (v) intangible asset amortization expense. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. The measure of net debt consists of GAAP total debt (excluding deferred financing costs) less short-term investments, cash and cash equivalents.
Reconciliations of GAAP revenues to organic revenues, GAAP net income to adjusted EBITDA, and adjusted net income, GAAP gross margin to adjusted gross margin, GAAP total debt to net debt, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the quarters ended March 31, 2025 and 2024.
The Company believes that the presentation of organic revenues and the other non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com.
Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | ||||||||
| (In thousands, except per share amounts) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Total revenues, net | $ | 382,653 | $ | 368,872 | ||||
| Costs and expenses: | ||||||||
| Cost of goods sold | 188,221 | 162,038 | ||||||
| Research and development | 24,728 | 26,965 | ||||||
| Selling, general and administrative | 181,497 | 165,798 | ||||||
| Intangible asset amortization | 3,704 | 10,107 | ||||||
| Total costs and expenses | 398,150 | 364,908 | ||||||
| Operating income (loss) | (15,497 | ) | 3,964 | |||||
| Interest income | 4,420 | 5,040 | ||||||
| Interest expense | (18,815 | ) | (13,624 | ) | ||||
| Other expense, net | (144 | ) | (610 | ) | ||||
| Loss before income taxes | (30,036 | ) | (5,230 | ) | ||||
| Income tax (benefit) | (4,743 | ) | (1,949 | ) | ||||
| Net Loss | (25,293 | ) | $ | (3,281 | ) | |||
| Net income per share: | ||||||||
| Diluted net loss per share | $ | (0.33 | ) | $ | (0.04 | ) | ||
| Weighted average common shares outstanding for diluted net income per share | 76,463 | 77,735 | ||||||
The following table presents revenues disaggregated by the major sources for the three months ended March 31, 2025 and 2024 (amounts in thousands):
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | Change | ||||||
| Neurosurgery | $ | 190,912 | 202,268 | (5.6 | )% | |||
| Instruments(1) | 50,950 | 44,373 | 14.8 | % | ||||
| ENT(1) | 38,802 | 9,793 | 296.2 | % | ||||
| Total Codman Specialty Surgical | 280,664 | 256,434 | 9.4 | % | ||||
| Wound Reconstruction and Care | 74,779 | 80,877 | (7.5 | )% | ||||
| Private Label | 27,210 | 31,561 | (13.8 | )% | ||||
| Total Tissue Technologies | 101,989 | 112,438 | (9.3 | )% | ||||
| Total reported revenues | $ | 382,653 | $ | 368,872 | 3.7 | % | ||
| Impact of changes in currency exchange rates | 2,236 | — | ||||||
| Less contribution of revenues from acquisitions | (29,092 | ) | — | |||||
| Total organic revenues(2) | $ | 355,798 | $ | 368,872 | (3.5 | )% | ||
(1) Prior period revenues included within our instruments business have been reclassified under the ENT business.
(2) Organic revenues have been adjusted to exclude foreign currency (current period), acquisitions and to account for divested and discontinued products.
| Items included in GAAP net income and location where each item is recorded are as follows: |
| (In thousands) |
| Three Months Ended March 31, 2025 |
| Item | Total Amount | COGS(a) | SG&A(b) | R&D(c) | Amort (d) | OI&E(e) | Tax(f) | |||
| Acquisition, divestiture and integration-related charges | 6,224 | 671 | 5,824 | (736 | ) | — | 464 | — | ||
| Structural Optimization charges | 10,663 | 4,276 | 6,436 | (50 | ) | — | — | — | ||
| EU Medical Device Regulation charges | 10,944 | 1,375 | 4,807 | 4,761 | — | — | — | |||
| Boston Recall/Braintree Transition | 14,810 | 14,386 | 424 | — | — | — | — | |||
| Intangible asset amortization expense | 26,473 | 22,769 | — | — | 3,704 | — | — | |||
| Estimated income tax impact from above adjustments and other items | (12,167 | ) | — | — | — | — | — | (12,167 | ) | |
| Depreciation expense | 10,456 | — | — | — | — | — | — | |||
a) COGS - Cost of goods sold
b) SG&A - Selling, general and administrative
c) R&D - Research & development
d) Amort. - Intangible asset amortization
e) OI&E - Other income & expense
f) Tax - Income tax expense (benefit)
| Items included in GAAP net income and location where each item is recorded are as follows: |
| (In thousands) |
| Three Months Ended March 31, 2024 |
| Item | Total Amount | COGS(a) | SG&A(b) | R&D(c) | Amort (d) | OI&E(e) | Tax(f) | ||||
| Acquisition, divestiture and integration-related charges | 4,723 | 50 | 4,802 | (83 | ) | — | (46 | ) | — | ||
| Structural Optimization charges | 4,440 | 3,320 | 1,118 | 2 | — | — | — | ||||
| EU Medical Device Regulation charges | 12,023 | 1,441 | 4,657 | 5,925 | — | — | — | ||||
| Boston Recall/Braintree Transition | 9,044 | 8,210 | 834 | — | — | — | — | ||||
| Intangible asset amortization expense | 27,698 | 17,591 | — | — | 10,107 | — | — | ||||
| Estimated income tax impact from above adjustments and other items | (11,696 | ) | — | — | — | — | — | (11,696 | ) | ||
| Depreciation expense | 9,899 | — | — | — | — | — | — | ||||
a) COGS - Cost of goods sold
b) SG&A - Selling, general and administrative
c) R&D - Research & development
d) Amort. - Intangible asset amortization
e) OI&E - Other income & expense
f) Tax - Income tax expense (benefit)
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO ADJUSTED EBITDA (UNAUDITED) | ||||||||
| (In thousands) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| GAAP net loss | $ | (25,293 | ) | $ | (3,281 | ) | ||
| Non-GAAP adjustments: | ||||||||
| Depreciation and intangible asset amortization expense | 36,929 | 37,597 | ||||||
| Other (income) expense, net | (320 | ) | 656 | |||||
| Interest expense, net | 14,394 | 8,584 | ||||||
| Income tax expense | (4,743 | ) | (1,949 | ) | ||||
| Structural optimization charges | 10,663 | 4,440 | ||||||
| EU Medical Device Regulation charges | 10,944 | 12,023 | ||||||
| Boston Recall/ Braintree transition | 14,810 | 9,044 | ||||||
| Acquisition, divestiture and integration-related charges | 6,224 | 4,723 | ||||||
| Total of non-GAAP adjustments | 88,902 | 75,118 | ||||||
| Adjusted EBITDA | $ | 63,609 | $ | 71,837 | ||||
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE (UNAUDITED) | ||||||||
| (In thousands, except per share amounts) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| GAAP net loss | $ | (25,293 | ) | $ | (3,281 | ) | ||
| Non-GAAP adjustments: | ||||||||
| Structural optimization charges | 10,663 | 4,440 | ||||||
| Acquisition, divestiture and integration-related charges | 6,224 | 4,723 | ||||||
| EU Medical Device Regulation charges | 10,944 | 12,023 | ||||||
| Boston Recall/Braintree Transition | 14,810 | 9,044 | ||||||
| Intangible asset amortization expense | 26,473 | 27,698 | ||||||
| Estimated income tax impact from adjustments and other items | (12,167 | ) | (11,696 | ) | ||||
| Total of non-GAAP adjustments | 56,947 | 46,231 | ||||||
| Adjusted net income | $ | 31,654 | $ | 42,950 | ||||
| Adjusted diluted net income per share | $ | 0.41 | $ | 0.55 | ||||
| Weighted average common shares outstanding for diluted net income per share | 76,586 | 77,958 | ||||||
| CONDENSED BALANCE SHEET DATA (UNAUDITED) | ||||||
| (In thousands) | ||||||
| March 31, 2025 | December 31, 2024 | |||||
| Short term investments | $ | 34,191 | $ | 27,192 | ||
| Cash and cash equivalents | 239,104 | 246,375 | ||||
| Trade accounts receivable, net | 252,446 | 272,370 | ||||
| Inventories, net | 445,418 | 429,090 | ||||
| Current and long-term borrowing under senior credit facility | 1,167,291 | 1,121,823 | ||||
| Borrowings under securitization facility | 102,100 | 108,100 | ||||
| Convertible securities | 573,899 | 573,170 | ||||
| Stockholders' equity | $ | 1,524,139 | $ | 1,545,280 | ||
| CONDENSED STATEMENT OF CASH FLOWS (UNAUDITED) | ||||||||
| (In thousands) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Net cash (used) provided by operating activities | $ | (11,257 | ) | $ | 15,756 | |||
| Net cash used in investing activities | (35,920 | ) | (53,965 | ) | ||||
| Net cash provided by (used by) by financing activities | 35,377 | 358,676 | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 4,529 | (4,963 | ) | |||||
| Net increase (decrease) in cash and cash equivalents | $ | (7,271 | ) | $ | 315,504 | |||
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING CASH FLOW TO MEASURES OF FREE CASH FLOW AND ADJUSTED FREE CASH FLOW CONVERSION (UNAUDITED) | |||||||
| (In thousands) | |||||||
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Net cash (used) provided by operating activities | $ | (11,257 | ) | $ | 15,756 | ||
| Purchases of property and equipment | $ | (28,920 | ) | $ | (15,465 | ) | |
| Free cash flow | (40,177 | ) | 291 | ||||
| Adjusted net income(1) | $ | 31,654 | $ | 42,950 | |||
| Adjusted free cash flow conversion | (126.9 | )% | 0.7 | % | |||
| Twelve Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Net cash provided by operating activities | $ | 102,368 | $ | 129,552 | |||
| Purchases of property and equipment | (117,872 | ) | (68,737 | ) | |||
| Free cash flow | $ | (15,504 | ) | $ | 60,815 | ||
| Adjusted net income(1) | $ | 185,652 | $ | 230,004 | |||
| Adjusted free cash flow conversion | (8.4 | )% | 26.4 | % | |||
(1) Adjusted net income for quarters ended March 31, 2025 and 2024 are reconciled above. Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations on our website at investor.integralife.com under Events & Presentations.
The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income. The Company believes this measure is useful in evaluating the significance of the cash special charges in its adjusted earnings measures.
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - NET DEBT CALCULATION (UNAUDITED) | |||||||
| (In thousands) | |||||||
| March 31, 2025 | December 31, 2024 | ||||||
| Short-term borrowings under senior credit facility | 38,750 | 33,906 | |||||
| Long-term borrowings under senior credit facility | 1,128,541 | 1,087,917 | |||||
| Borrowings under securitization facility | 102,100 | 108,100 | |||||
| Convertible securities | 573,899 | 573,170 | |||||
| Deferred financing costs netted in the above | 4,436 | 5,475 | |||||
| Short term investments | (34,191 | ) | (27,192 | ) | |||
| Cash & Cash Equivalents | (239,104 | ) | (246,375 | ) | |||
| Net Debt | $ | 1,574,431 | $ | 1,535,001 | |||
| RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP GROSS PROFIT TO MEASURES OF ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN (UNAUDITED) | ||||||||
| (In thousands, except percentages) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Total revenues, net | $ | 382,653 | $ | 368,872 | ||||
| Cost of goods sold | 188,221 | 162,038 | ||||||
| Reported Gross Profit | 194,432 | 206,834 | ||||||
| Structural optimization charges | 4,276 | 3,320 | ||||||
| Acquisition, divestiture and integration-related charges | 671 | 50 | ||||||
| Boston Recall/Braintree Transition | 14,386 | 8,210 | ||||||
| EU Medical Device Regulation | 1,375 | 1,441 | ||||||
| Intangible asset amortization expense | 22,769 | 17,591 | ||||||
| Adjusted Gross Profit | $ | 237,909 | $ | 237,446 | ||||
| Total Revenues | $ | 382,653 | $ | 368,872 | ||||
| Adjusted Gross Margin | 62.2 | % | 64.4 | % | ||||
FAQ
What were Integra LifeSciences (IART) Q1 2025 earnings results?
How did IART's different segments perform in Q1 2025?
What is Integra's revenue guidance for full-year 2025?
How will new tariffs impact IART's earnings in 2025?
What is IART's debt position as of Q1 2025?
